| KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005) | |||||||||||||
Abstract | |||||||||||||
| Mutational analysis of the KRAS gene in lung cancer patients treated with two different kinase inhibitors suggests that tumors with KRAS mutations do not respond to these drugs. | |||||||||||||
Publication details | |||||||||||||
| |||||||||||||